Demyelinating Diseases  >>  GZ402668  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GZ402668 / Sanofi
NCT02282826: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

Completed
1
48
Europe
GZ402668, placebo, acyclovir
Genzyme, a Sanofi Company
Progressive Multiple Sclerosis
03/16
03/16

Download Options